Arvinas Holding Company LLC(ARVN)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

ARVN Arvinas Holding Company LLC

交易中 07-02 15:48:20 EDT

8.36

+0.16

+1.95%

最高8.67	最低8.16	成交量45.24万
今开8.24	昨收8.20	日振幅6.28%
总市值5.37亿	流通市值5.37亿	总股本6,422万
成交额381.63万	换手率0.70%	流通股本6,422万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"ARVN","market":"US","secType":"STK","nameCN":"Arvinas Holding Company LLC","latestPrice":8.36,"timestamp":1783021699089,"preClose":8.2,"halted":0,"volume":452447,"delay":0,"changeRate":0.019512195121951237,"floatShares":64224294,"shares":64224294,"eps":-3.217739,"marketStatus":"交易中","change":0.16,"latestTime":"07-02 15:48:20 EDT","open":8.24,"high":8.67,"low":8.155,"amount":3816255.6157939998,"amplitude":0.062805,"askPrice":8.36,"askSize":450,"bidPrice":8.34,"bidSize":420,"shortable":3,"etf":0,"ttmEps":-3.217739,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1783022400000},"marketStatusCode":2,"adr":0,"adrRate":0,"listingDate":1538020800000,"exchange":"NASDAQ","adjPreClose":8.2,"preHourTrading":{"tag":"盘前","latestPrice":8.1,"preClose":8.2,"latestTime":"08:31 EDT","volume":1296,"amount":10713.188304,"timestamp":1782995465079,"change":-0.1,"changeRate":-0.012195,"amplitude":0.078049},"postHourTrading":{"tag":"盘后","latestPrice":8.1988,"preClose":8.2,"latestTime":"16:14 EDT","volume":70537,"amount":578403.1228,"timestamp":1782936865455,"change":-0.0012,"changeRate":-0.000146,"amplitude":0.000146},"volumeRatio":0.394045,"impliedVol":0.7441,"impliedVolPercentile":0.7131},"requestUrl":"/m/hq/s/ARVN","defaultTab":"news","newsList":[{"id":"1196083011","title":"Arvinas与辉瑞有望获得高达3.2亿美元的里程碑付款及分层特许权使用费——SEC文件披露","url":"https://stock-news.laohu8.com/highlight/detail?id=1196083011","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1196083011?lang=zh_cn&edition=full","pubTime":"2026-06-17 04:34","pubTimestamp":1781642069,"startTime":"0","endTime":"0","summary":"根据一份提交给美国证券交易委员会的文件披露，Arvinas Holding Company LLC与辉瑞公司合作的一项协议显示，双方有资格获得总计高达3.2亿美元的里程碑付款，并附有分层结构的特许权使用费安排。分层特许权使用费则意味着，随着产品销售额达到不同阈值，费率将相应调整，这为双方提供了更具弹性的收益分享机制。协议的细节虽未完全公开，但高达3.2亿美元的总潜在收益，无疑为项目的后续发展注入了强劲的财务动力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ARVN","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1108839680","title":"Arvinas、辉瑞与Rigel于2026年6月11日获HSR批准达成许可协议 - 美国证券交易委员会文件披露","url":"https://stock-news.laohu8.com/highlight/detail?id=1108839680","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1108839680?lang=zh_cn&edition=full","pubTime":"2026-06-17 04:32","pubTimestamp":1781641938,"startTime":"0","endTime":"0","summary":"根据一份提交给美国证券交易委员会的文件，生物技术公司Arvinas Holding Company LLC、制药巨头辉瑞以及Rigel Pharmaceuticals于2026年6月11日获得了《哈特-斯科特-罗迪诺反垄断改进法案》的批准。这一关键进展为各方推进此前宣布的许可协议扫清了监管障碍。此举通常意味着监管机构认定该交易不会对相关市场的竞争构成实质性损害。随着监管门槛的跨越，各方预计将加速执行许可协议的具体条款，推动相关研发或商业化项目的进展。这一动态受到行业观察者的密切关注。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ARVN","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1182949257","title":"Arvinas加入迈克尔·J·福克斯基金会LITE和PPMI项目，共同推进针对帕金森病LRRK2靶点的新疗法研发","url":"https://stock-news.laohu8.com/highlight/detail?id=1182949257","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1182949257?lang=zh_cn&edition=full","pubTime":"2026-06-04 20:02","pubTimestamp":1780574550,"startTime":"0","endTime":"0","summary":"Arvinas Holding Company LLC宣布加入迈克尔·J·福克斯基金会的LITE和PPMI两大研究项目，旨在加速开发针对帕金森病关键靶点LRRK2的创新疗法。这一合作将整合多方资源，推动前沿科学探索与临床转化进程，为帕金森病患者带来新的治疗希望。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ARVN","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1133889852","title":"Arvinas：截至2026年3月31日的现金头寸预计将支撑运营至2028年下半年——SEC文件披露","url":"https://stock-news.laohu8.com/highlight/detail?id=1133889852","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1133889852?lang=zh_cn&edition=full","pubTime":"2026-06-03 04:41","pubTimestamp":1780432917,"startTime":"0","endTime":"0","summary":"根据提交给美国证券交易委员会（SEC）的文件，生物制药公司Arvinas Holding Company LLC披露，其截至2026年3月31日的现金及现金等价物状况，预计足以支持公司的运营活动延续至2028年下半年。这一资金预期为公司的长期研发和业务发展提供了明确的财务保障。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ARVN","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1152908704","title":"Arvinas 计划为 ARV-806 额外临床试验寻求外部授权协议——SEC 文件披露","url":"https://stock-news.laohu8.com/highlight/detail?id=1152908704","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1152908704?lang=zh_cn&edition=full","pubTime":"2026-06-03 04:41","pubTimestamp":1780432902,"startTime":"0","endTime":"0","summary":"根据提交给美国证券交易委员会的文件，生物制药公司 Arvinas Holding Company LLC 披露，公司计划为其在研药物 ARV-806 寻求外部授权合作协议，以推进额外的临床试验。这一战略举措旨在通过引入外部合作伙伴，为 ARV-806 的进一步临床开发获取必要的资源与专业支持。ARV-806 是 Arvinas 研发管线中的一款候选药物。后续临床试验的具体范围与设计，预计将在达成协议后进一步明确。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ARVN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1163342588","title":"Arvinas计划于2026年完成I期单药剂量递增试验并分享数据——SEC文件披露","url":"https://stock-news.laohu8.com/highlight/detail?id=1163342588","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1163342588?lang=zh_cn&edition=full","pubTime":"2026-06-03 04:41","pubTimestamp":1780432881,"startTime":"0","endTime":"0","summary":"根据提交给美国证券交易委员会（SEC）的文件，生物技术公司Arvinas Holding Company LLC计划在2026年完成其I期单药剂量递增临床试验，并届时公布相关数据。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ARVN","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1157887878","title":"Arvinas与辉瑞携手Rigel Pharmaceuticals，就Veppanu（Vepdegestrant）达成全球独家授权交易","url":"https://stock-news.laohu8.com/highlight/detail?id=1157887878","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1157887878?lang=zh_cn&edition=full","pubTime":"2026-05-12 19:01","pubTimestamp":1778583714,"startTime":"0","endTime":"0","summary":"Arvinas Holding Company LLC与辉瑞公司已同Rigel Pharmaceuticals达成一项协议，获得其药物Veppanu（Vepdegestrant）的全球独家权利。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0122379950.USD","LU1883839398.USD","IE0002270589.USD","BK4568","LU0170899867.USD","BK4592","BK4585","IE00B3T34201.USD","LU1894683264.USD","LU1057294990.SGD","IE00B19Z3581.USD","SG9999003800.SGD","RIGL","SG9999011175.SGD","LU0225771236.USD","IE00BLSP4239.USD","SG9999013999.USD","LU0058720904.USD","LU0289739699.SGD","LU1023059063.AUD","IE00BBT3K403.USD","LU0985481810.HKD","SGXZ57979304.SGD","BK4550","LU0321505868.SGD","LU0306806265.USD","LU1066053197.SGD","PFE","IE00B19Z3B42.SGD","BK4534","LU1066051498.USD","BK4007","IE000M9KFDE8.USD","SG9999001176.SGD","SG9999002232.USD","LU0456855351.SGD","LU0868494617.USD","BK4533","SG9999001176.USD","LU0225284248.USD","BK4581","BK4588","IE00BLSP4452.SGD","ARVN","LU0321505439.SGD","LU1894683348.USD","SG9999002224.SGD","LU0306807586.USD","LU0234572021.USD","BK4599"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1131483490","title":"Arvinas宣布Veppanu（Vepdegestrant）获FDA批准用于治疗ESR1突变、ER+/HER2-晚期乳腺癌","url":"https://stock-news.laohu8.com/highlight/detail?id=1131483490","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1131483490?lang=zh_cn&edition=full","pubTime":"2026-05-02 00:46","pubTimestamp":1777653983,"startTime":"0","endTime":"0","summary":"生物制药公司Arvinas Holding Company LLC（简称Arvinas）迎来重大里程碑——其创新药物Veppanu（通用名：Vepdegestrant）正式获得美国食品药品监督管理局（FDA）的上市批准。该药物将用于治疗携带ESR1突变、雌激素受体阳性且人表皮生长因子受体2阴性的晚期乳腺癌患者。\n此次获批为特定乳腺癌亚型患者提供了新的治疗选择，标志着Arvinas在蛋白降解疗法领域取得了实质性突破。Veppanu作为一种新型的口服PROTAC蛋白降解剂，其作用机制旨在选择性地靶向并降解雌激素受体，为面临治疗挑战的晚期乳腺癌患者带来新的希望。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ARVN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1148874826","title":"Arvinas帕金森病新药ARV-102一期临床数据亮眼，28天治疗实现脑脊液LRRK2蛋白降解超50%","url":"https://stock-news.laohu8.com/highlight/detail?id=1148874826","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1148874826?lang=zh_cn&edition=full","pubTime":"2026-03-18 19:03","pubTimestamp":1773831834,"startTime":"0","endTime":"0","summary":"生物技术公司Arvinas Holding Company LLC近日公布其针对帕金森病的新型靶向蛋白降解疗法ARV-102的一期临床试验积极数据。结果显示，在接受28天治疗后，患者脑脊液中的LRRK2蛋白水平下降超过50%，达到了研究的主要生物标志物终点。ARV-102采用Arvinas专有的PROTAC技术平台设计，旨在特异性降解与帕金森病发病密切相关的LRRK2蛋白。分析师指出，ARV-102的早期积极数据增强了市场对Arvinas技术平台扩展性的信心。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ARVN","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1154525693","title":"Arvinas阿尔法突触核蛋白降解剂ARV-102一期临床展现良好耐受性，单日一次给药28天安全数据积极","url":"https://stock-news.laohu8.com/highlight/detail?id=1154525693","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1154525693?lang=zh_cn&edition=full","pubTime":"2026-03-18 19:03","pubTimestamp":1773831806,"startTime":"0","endTime":"0","summary":"生物制药公司Arvinas今日宣布，其针对帕金森病等神经退行性疾病开发的阿尔法突触核蛋白靶向蛋白降解剂ARV-102，在完成一期临床单次及多次递增剂量研究后，显示出良好的安全性与耐受性特征。根据公司披露，在为期28天、每日一次给药的研究中，ARV-102在所有剂量水平下均表现出良好的耐受性。公司表示，基于当前的一期临床结果，将继续推进ARV-102的临床开发计划，下一步研究重点将包括在患者群体中评估其生物活性和初步疗效信号。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ARVN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618991322","title":"Arvinas, Inc.盘中异动 早盘股价大涨7.03%","url":"https://stock-news.laohu8.com/highlight/detail?id=2618991322","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618991322?lang=zh_cn&edition=full","pubTime":"2026-03-10 21:32","pubTimestamp":1773149578,"startTime":"0","endTime":"0","summary":"北京时间2026年03月10日21时32分，Arvinas, Inc.股票出现波动，股价大幅上涨7.03%。Arvinas, Inc.股票所在的生物技术行业中，整体涨幅为1.36%。Arvinas, Inc.公司简介：Arvinas Inc 是一家临床阶段的生物技术公司，致力于通过发现、开发和商业化降解致病蛋白的疗法，改善罹患衰弱性疾病和危及生命的疾病患者的生活。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260310213258a45ec083&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260310213258a45ec083&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ARVN","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617657724","title":"Arvinas, Inc.盘中异动 股价大跌5.10%","url":"https://stock-news.laohu8.com/highlight/detail?id=2617657724","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617657724?lang=zh_cn&edition=full","pubTime":"2026-03-07 00:57","pubTimestamp":1772816220,"startTime":"0","endTime":"0","summary":"北京时间2026年03月07日00时57分，Arvinas, Inc.股票出现波动，股价快速跳水5.10%。Arvinas, Inc.股票所在的生物技术行业中，整体跌幅为1.31%。Arvinas, Inc.公司简介：Arvinas Inc 是一家临床阶段的生物技术公司，致力于通过发现、开发和商业化降解致病蛋白的疗法，改善罹患衰弱性疾病和危及生命的疾病患者的生活。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260307005701a4549b27&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260307005701a4549b27&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","ARVN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1155813114","title":"Arvinas将于2026年2月24日公布2025年第四季度及全年财务业绩","url":"https://stock-news.laohu8.com/highlight/detail?id=1155813114","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1155813114?lang=zh_cn&edition=full","pubTime":"2026-02-17 20:04","pubTimestamp":1771329862,"startTime":"0","endTime":"0","summary":"康涅狄格州纽黑文，2026年2月17日——临床阶段生物技术公司Arvinas, Inc.今日宣布，公司管理层将于2026年2月24日（星期二）美国东部时间上午8:00举行网络直播，回顾2025年第四季度及全年财务业绩，并提供公司最新动态。此次网络直播可通过Arvinas官方网站投资者关系页面的\"活动与演示\"栏目观看。Arvinas是一家临床阶段的生物技术公司，致力于改善患有衰弱性和危及生命疾病的患者的生活。Arvinas公司总部位于康涅狄格州纽黑文。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ARVN","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1186467262","title":"Arvinas任命Randy Teel博士为总裁、首席执行官兼董事","url":"https://stock-news.laohu8.com/highlight/detail?id=1186467262","media":"投资观察","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1186467262?lang=zh_cn&edition=full","pubTime":"2026-02-12 20:06","pubTimestamp":1770898006,"startTime":"0","endTime":"0","summary":"Arvinas公司今日宣布，任命Randy Teel博士担任公司总裁兼首席执行官，并进入董事会，即日生效。Teel博士此前担任Arvinas首席商务官，以其推动企业成长与行业合作的战略领导力著称。此次人事变动源于原总裁兼首席执行官John Houston博士退休。同日，Briggs Morrison博士当选为董事会主席。在加入Arvinas前，他曾任Alexion Pharmaceuticals战略副总裁及麦肯锡公司副合伙人。Arvinas是一家临床阶段生物技术公司，致力于通过PROTAC蛋白降解技术平台开发创新疗法。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ARVN","BK4007","CEO","IPO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1101957887","title":"Arvinas任命Randy Teel博士为总裁、首席执行官兼董事","url":"https://stock-news.laohu8.com/highlight/detail?id=1101957887","media":"美股速递","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1101957887?lang=zh_cn&edition=full","pubTime":"2026-02-12 20:02","pubTimestamp":1770897721,"startTime":"0","endTime":"0","summary":"Arvinas Holding Company LLC宣布，任命Randy Teel博士担任公司总裁、首席执行官及董事职务。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ARVN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2610946885","title":"Arvinas, Inc.盘中异动 股价大跌5.13%","url":"https://stock-news.laohu8.com/highlight/detail?id=2610946885","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610946885?lang=zh_cn&edition=full","pubTime":"2026-02-11 22:51","pubTimestamp":1770821466,"startTime":"0","endTime":"0","summary":"北京时间2026年02月11日22时51分，Arvinas, Inc.股票出现波动，股价快速下跌5.13%。Arvinas, Inc.股票所在的生物技术行业中，整体跌幅为0.93%。Arvinas, Inc.公司简介：Arvinas Inc 是一家总部位于美国的生物制药公司，致力于通过发现、开发和商业化降解致病蛋白质的疗法来改善患有使人衰弱和危及生命的疾病的患者的生活。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026021122510797a5d2d2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026021122510797a5d2d2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","ARVN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2518745334","title":"辉瑞乳腺癌新药Vepdegestrant研究喜忧参半，授权方Arvinas股价暴跌40%","url":"https://stock-news.laohu8.com/highlight/detail?id=2518745334","media":"智通财经网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518745334?lang=zh_cn&edition=full","pubTime":"2025-03-11 20:59","pubTimestamp":1741697953,"startTime":"0","endTime":"0","summary":"辉瑞公司的下一代乳腺癌治疗药物 vepdegestrant 在最后阶段的研究中取得了好坏参半的结果，未能延缓所有患者的癌症进展，但达到了针对具有特定基因突变的亚组患者的目标。","market":"hk","thumbnail":"https://static.tigerbbs.com/f874ded00c644297784368a7af94c8ae","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/f874ded00c644297784368a7af94c8ae"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1260559.html","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK4585","BK4592","LU0225771236.USD","BK4588","IE0002270589.USD","LU0321505868.SGD","LU0170899867.USD","LU0225284248.USD","PFE","IE00BBT3K403.USD","LU0306806265.USD","LU1057294990.SGD","IE00B19Z3B42.SGD","LU1066053197.SGD","BK4599","BK4550","BK4007","LU0234572021.USD","LU0321505439.SGD","BK4533","LU0058720904.USD","LU0289739699.SGD","LU1023059063.AUD","LU0985481810.HKD","LU1894683264.USD","LU1066051498.USD","LU1894683348.USD","IE00B19Z3581.USD","BK4534","SG9999001176.SGD","LU0456855351.SGD","LU0122379950.USD","LU0868494617.USD","SG9999003800.SGD","SG9999013999.USD","SGXZ57979304.SGD","IE000M9KFDE8.USD","ARVN","IE00BLSP4452.SGD","SG9999002232.USD","BK4581","IE00BLSP4239.USD","BK4568","LU0306807586.USD","SG9999002224.SGD","LU1883839398.USD","SG9999001176.USD","SG9999011175.SGD"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2518495206","title":"Arvinas, Inc.盘中异动 下午盘股价大跌5.14%报17.34美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2518495206","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518495206?lang=zh_cn&edition=full","pubTime":"2025-03-11 02:13","pubTimestamp":1741630432,"startTime":"0","endTime":"0","summary":"北京时间2025年03月11日02时13分，Arvinas, Inc.股票出现异动，股价急速下挫5.14%。截至发稿，该股报17.34美元/股，成交量57.7109万股，换手率0.84%，振幅6.04%。Arvinas, Inc.股票所在的生物技术行业中，整体涨幅为0.68%。Arvinas, Inc.公司简介：Arvinas Inc 是一家总部位于美国的生物制药公司，致力于通过发现、开发和商业化降解致病蛋白质的疗法来改善患有使人衰弱和危及生命的疾病的患者的生活。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025031102135298a2d48d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025031102135298a2d48d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","ARVN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2517693254","title":"花旗：维持Arvinas(ARVN.US)评级，由中性调整至中性评级, 目标价由28.00美元调整至19.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2517693254","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517693254?lang=zh_cn&edition=full","pubTime":"2025-03-08 05:50","pubTimestamp":1741384237,"startTime":"0","endTime":"0","summary":"花旗：维持Arvinas(ARVN.US)评级，由中性调整至中性评级, 目标价由28.00美元调整至19.00美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/03/08055048605286.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["ARVN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2517194729","title":"Arvinas, Inc.盘中异动 下午盘急速拉升5.20%","url":"https://stock-news.laohu8.com/highlight/detail?id=2517194729","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517194729?lang=zh_cn&edition=full","pubTime":"2025-03-07 03:38","pubTimestamp":1741289911,"startTime":"0","endTime":"0","summary":"北京时间2025年03月07日03时38分，Arvinas, Inc.股票出现异动，股价急速拉升5.20%。Arvinas, Inc.股票所在的生物技术行业中，整体跌幅为0.75%。Arvinas, Inc.公司简介：Arvinas Inc 是一家总部位于美国的生物制药公司，致力于通过发现、开发和商业化降解致病蛋白质的疗法来改善患有使人衰弱和危及生命的疾病的患者的生活。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250307033831989ee96f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250307033831989ee96f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ARVN","BK4007"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.arvinas.com","stockEarnings":[{"period":"1week","weight":0.0186},{"period":"1month","weight":-0.0443},{"period":"3month","weight":-0.2442},{"period":"6month","weight":-0.2851},{"period":"1year","weight":0.0747},{"period":"ytd","weight":-0.3086}],"compareEarnings":[{"period":"1week","weight":0.0171},{"period":"1month","weight":-0.0168},{"period":"3month","weight":0.1371},{"period":"6month","weight":0.0916},{"period":"1year","weight":0.2074},{"period":"ytd","weight":0.0936}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Arvinas, Inc.于2013年2月根据特拉华州法律成立。该公司是一家生物制药公司，致力于通过发现、开发和商业化治疗降低致病蛋白质来改善患有衰弱和危及生命的疾病的患者的生活。该公司使用他们的专有技术平台来设计针对嵌合体或PROTAC的蛋白水解，这些嵌合体旨在利用人体自身的天然蛋白质处理系统来选择性地和有效地降解和去除致病蛋白质。Arvinas Holding Company，LLC相信他们的靶向蛋白质降解方法是一种新的治疗方式，可能提供优于现有方式的独特优势，包括传统的小分子疗法和基于基因的药物。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.038223},{"month":2,"riseRate":0.5,"avgChangeRate":0.008648},{"month":3,"riseRate":0.125,"avgChangeRate":-0.189422},{"month":4,"riseRate":0.5,"avgChangeRate":0.076221},{"month":5,"riseRate":0.375,"avgChangeRate":-0.127354},{"month":6,"riseRate":0.75,"avgChangeRate":0.001907},{"month":7,"riseRate":0.625,"avgChangeRate":0.094288},{"month":8,"riseRate":0.285714,"avgChangeRate":-0.06004},{"month":9,"riseRate":0.285714,"avgChangeRate":-0.073956},{"month":10,"riseRate":0.5,"avgChangeRate":0.007881},{"month":11,"riseRate":0.75,"avgChangeRate":0.171233},{"month":12,"riseRate":0.5,"avgChangeRate":0.349087}],"exchange":"NASDAQ","name":"Arvinas Holding Company LLC","nameEN":"Arvinas Holding Company LLC"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Arvinas Holding Company LLC(ARVN)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Arvinas Holding Company LLC(ARVN)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Arvinas Holding Company LLC,ARVN,Arvinas Holding Company LLC股票,Arvinas Holding Company LLC股票老虎,Arvinas Holding Company LLC股票老虎国际,Arvinas Holding Company LLC行情,Arvinas Holding Company LLC股票行情,Arvinas Holding Company LLC股价,Arvinas Holding Company LLC股市,Arvinas Holding Company LLC股票价格,Arvinas Holding Company LLC股票交易,Arvinas Holding Company LLC股票购买,Arvinas Holding Company LLC股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Arvinas Holding Company LLC(ARVN)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Arvinas Holding Company LLC(ARVN)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}